Acute Urinary Retention Rates in the General Male Population and in Adult Men With Lower Urinary Tract Symptoms Participating in Pharmacotherapy Trials: A Literature Review.

Abstract

Despite proven efficacy, antimuscarinics are not frequently used for treating lower urinary tract symptoms in adult men, due to the perception of an increased risk of acute urinary retention (AUR). Men treated with α-blockers, 5α-reductase inhibitors, or their combinations have lower AUR incidence rates than the general symptomatic population. In the selected study population in this review (men with post-void residuals ≤200 mL), the risk of AUR with antimuscarinics with and/or without α-blockers may be increased during short-term treatment, but if patients do not develop AUR in the first 3 months, their subsequent risk is lower than in the untreated, symptomatic population.

• Authors: Matthias Oelke, Mark J Speakman, François Desgrandchamps, Charalampos Mamoulakis
• Journal: Urology (Urology) Vol. 86 Issue 4 Pg. 654-65 (Oct 2015) ISSN: 1527-9995 [Electronic] United States
• PMID: 26142712 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2015 Elsevier Inc. All rights reserved.

Chemical References

• Urological Agents

Topics

• Adult
• Clinical Trials as Topic
• Global Health
• Humans
• Lower Urinary Tract Symptoms (complications, epidemiology, therapy)
• Male
• Morbidity (trends)
• Risk Factors
• Urinary Retention (drug therapy, epidemiology, etiology)
• Urological Agents (therapeutic use)